Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

OpenAI announced Thursday that it has entered into an agreement to acquire Astral, the company behind popular open source Python development tools such as uv, Ruff, and ty, and integrate the company ...

UC San Diego cognitive scientist Philip Guo created Python Tutor, a free tool that makes code “visible” step by step. The research behind it earned a Test of Time award, recog ...

Computational Modeling of Failure at the Fabric Weave Level in Reentry Parachute Energy ModulatorsEnergy modulators (EM) are textile ...

Atek Midas, a Turkish company, has launched DSG-22.6 GHz, a high-performance, open-source RF signal generator designed to provide professional-grade ...

It's time to join the Pythonistas.

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...